Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer

Heidi Fettke, Edmond M. Kwan, Patricia Bukczynska, Nicole Ng, Tu Nguyen-Dumont, Melissa C. Southey, Ian D. Davis, Andrew Mant, Phillip Parente, Carmel Pezaro, Christine Hauser, Arun A. Azad

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)


A higher total cell-free DNA (cfDNA) level is a poor prognosticator in advanced prostate cancer patients receiving novel hormonal therapies. Additionally, an early on-treatment rise in cfDNA levels predicts for better outcomes. Therefore, total cfDNA concentration may assist in prognostication and predicting treatment outcome.

Original languageEnglish
Pages (from-to)1287-1291
Number of pages5
JournalEuropean Urology Focus
Publication statusPublished - Nov 2021


  • Abiraterone
  • Androgen receptor pathway inhibitor
  • Biomarker
  • Castrate resistant
  • Cell-free DNA
  • Enzalutamide
  • Liquid biopsy
  • Prostate cancer

Cite this